In this private and highly anticipated round table discussion, leading Healthcare investor HLM Venture Partners, joined with portfolio companies and a family office LP, discuss 2021 market trends in digital health investing, present key trends to follow, and discuss an opportunity to invest in a late stage growth equity fund.
General Partner, HLM Venture Partners
Enrico Picozza is a pioneer in the life sciences with a history of recognizing and developing new technologies that change markets. He is currently a director of AbleTo, Dermtech (NASDQ), mPulse Mobile and RubiconMD and a board observer at LetsGetChecked and OnShift. Enrico also served as a director to Vericare (sold to MedOptions), Spinal Kinetics (sold to Orthofix), Aventura (sold to Philips), Medicalis (sold to Siemens), SensAble Technologies (sold to 3D Systems) and Transcend Medical (acquired by Alcon) and was a board observer and special advisor to Interlace Medical (sold to Hologic) and Tandem Diabetes (NASDAQ). Prior to joining HLM as a Venture Partner, Enrico co-founded HTS Biosystems, Inc., an early developer of platforms for drug discovery and point of care diagnostics, where he served as Chief Operating Officer and Chief Technology Officer.
Prior to HTS, Enrico held leadership positions with PerkinElmer, Inc. and Applied Biosystems, Inc. At Applied Biosystems, Enrico was one of the major forces behind the development and commercialization of PCR, the revolutionary DNA-replicating technology that enabled the development of some of the most significant advancements in molecular biology. He is the holder of nine patents and has been recognized by the Smithsonian Institute for his achievements in PCR. Enrico is the author of numerous scientific papers and has been a frequent international speaker. He earned his master’s degree in molecular and cell biology from the University of Connecticut.
General Partner, HLM Venture Partners
Steven Tolle is a partner with HLM Venture Partners. He brings to HLM 30 years of commercial healthcare technology expertise in the areas of strategy, business development, and product management. Steve has spent his career helping to develop and manage some of the most important themes in healthcare innovation and investment today, including artificial intelligence, diagnostic imaging/medical devices, electronic health records, population health, managed care and value-based pharmaceutical pricing.
Prior to joining HLM, Steve was global Vice President of Strategy at IBM Watson Health. Previously, he was Chief Strategy Officer at Merge Healthcare (acquired by IBM for $1B in 2015). Steve led the effort to move Merge Healthcare into the AI space and played a key role in the successful sale to IBM. As part of the Merge/Watson Health leadership team, Steve worked on over $3.6 billion of strategic M&A deal opportunities.
Other notable previous roles include Senior Vice President/General Manager at Optum, Vice President of Product Management at Allscripts, and Director of Product Management at Pfizer.
CEO, mPulse Mobile
Chris Nicholson is the Chief Executive Officer and co-founder of mPulse Mobile, a HIPAA compliant communication solution that enables health care payers and providers to interact with patients in Conversational AI. Chris has over 20 years of healthcare and technology leadership experience. Prior to joining mPulse, Chris spent over a decade in strategic leadership roles at Humana, a Fortune 100 healthcare company. Most recently, Chris served as the VP and COO of Wellness for Humana, a role in which he was responsible for managing a $200M+ P&L and integrating five acquired companies to build the second largest wellness company in the U.S.
Chairman of the Board of Intelligent Medical Objects, and a family-office investor in HLM Venture Partners
Frank Naeymi-Rad is the Chairman of the Board and co-founder of Intelligent Medical Objects, Inc. where he leads a team of informaticists and clinicians as they deliver industry-leading medical terminology services for electronic medical records (EMR) systems to over 3,900 hospitals and 450,000 clinicians daily. He was also co-founder of Intelligent Medical Systems, Inc., which was sold to Glaxo in 1994. His entrepreneurial spirit has led to a new vision of medical informatics embodied by codified semantics and natural language processing to eliminate isolated repositories of information and enable both patients and practitioners to make better use of health information. His thought leadership in clinical informatics led to nomination for the Oracle Corporation Smithsonian Award in the category of Medicine.
CEO of RubiconMD, an HLM portfolio company
Gil drives RubiconMD’s vision and strategy. He is passionate about improving access to the right medical expertise. Formerly a Consultant at Putnam Associates, a pharma strategy consultancy, Gil designed payer and market access strategies for Fortune 500s. He holds a BS in Economics and Biomedical Engineering from Yale and an MBA from Harvard. Gil was named one of Forbes Magazine’s “30 Under 30” in healthcare and included in Crain’s New York’s 2020 Notable in Health Care list.